Pacific Edge Limited (PEB.AX)
ASX · AUD · Healthcare · Diagnostics & Research
A$0.19 (+0.00%) as of
Key statistics
- Market cap
- 235.96M
- EPS (TTM)
- -0.0300
- Dividend yield
- 0.00%
- 52-week range
- 0.1200 – 0.2650
- Beta
- 0.84
- Revenue (TTM)
- 13.01M
- Profit margin
- -274.96%
- Volume
- 5.23k
About Pacific Edge Limited
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbladder Detect, which improve practice workflow and efficiency in urological care; Cxbladder Triage Plus, a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a recurrent non-muscle invasive bladder cancer. In addition, the company is developing products for bladder, gastric, colorectal and endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Dunedin, New Zealand
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.